Pharmacotherapy for Mild Hypertension

Brooke Lemmen, DO
Bindusri Paruchuri, MD

American Family Physician. 2026;114(5):465A-465B.

Author Disclosure: No relevant financial relationships.

DETAILS FOR THIS REVIEW

Study Population: 9,124 nonpregnant adults (18 years or older) with mild hypertension (systolic blood pressure 140–159 mm Hg or diastolic blood pressure 90–99 mm Hg) and no previous hypertensive treatment or underlying cardiovascular disease (CVD)

Efficacy End Points: All-cause mortality, total cardiovascular events, stroke, and coronary heart disease

Harm End Points: Study withdrawal due to medication adverse effects

Narrative: As quality measures in health care become increasingly numerous and complex, hypertension management has emerged as a key indicator of care quality. However, the benefits of primary prevention and treatment of mild hypertension in patients without prior CVD remain poorly understood. In particular, the financial and clinical implications of initiating lifelong medication in otherwise asymptomatic individuals have not been well studied.

Previous Cochrane reviews examined patients already being treated for mild hypertension, but this review assessed the effects of pharmacologic treatment for hypertension initiated as primary prevention in patients without underlying CVD. Examined outcomes included all-cause mortality, total cardiovascular events, stroke, coronary heart disease, and treatment withdrawal due to adverse effects.1

Low-certainty evidence demonstrated that pharmacotherapy for mild hypertension likely reduced stroke risk compared with placebo (relative risk = 0.41; 95% CI, 0.20–0.84; absolute risk difference = 0.4%; number needed to treat = 250; n = 7,292; four randomized controlled trials [RCTs]).

Low-certainty evidence demonstrated that pharmacotherapy increased study withdrawals due to medication adverse effects compared with placebo (relative risk = 4.80; 95% CI, 4.14–5.57; absolute risk difference = 8.7%; number needed to harm = 11; n = 17,354; one RCT).

THE NUMBERS

Benefits
1 in 250 had reduced risk of stroke
Harms
1 in 11 withdrew from the study due to adverse effects

Note: No deaths, cardiovascular events, or coronary heart disease were prevented.

The studies showed little to no difference in all-cause mortality, total cardiovascular events, and coronary heart disease between pharmacotherapy and placebo.

Caveats: Recent studies on hypertensive pharmacotherapy have included patients with higher systolic or diastolic blood pressure values (moderate to severe or resistant hypertension) and underlying cardiovascular conditions (eg, previous history of myocardial infarction, stroke, or coronary artery disease).2 Additional reviews have noted more severe adverse effects with antihypertensive pharmacotherapy, including syncope and acute kidney injury.3

The small number of strokes in the current Cochrane review (35 total) limit generalizability. Additional limitations include underpowered RCTs, use of older studies (most recent from 2004), and lack of equity-based assessments. Only one RCT examined study withdrawals, and a detailed evaluation of preexisting CVD for each participant was not possible.1

The antihypertensive medications in this Cochrane review (eg, bendrofluazide, propranolol, methyldopa) are no longer available in the United States or are not first-line antihypertensive medications per the American College of Cardiology/American Heart Association or the American Academy of Family Physicians clinical practice guidelines.1,4,5 This further limits clinical applicability.

Conclusion: Given the low-certainty evidence and small number of adverse events, we have assigned a color recommendation of yellow (unclear benefits) for pharmacologic interventions in adults with mild hypertension and no known CVD. Further research and use of more guideline-recommended medications would aid in validating pharmacotherapy in this population.

BROOKE LEMMEN, DO, is core faculty at the University of Michigan Health Sparrow/Michigan State University Family Medicine Residency and vice chair in the Department of Family Medicine, University of Michigan Health Sparrow, Lansing.

BINDUSRI PARUCHURI, MD, FAAFP, is an assistant professor and core faculty in the Department of Family Medicine, University of Tennessee Health Science Center College of Medicine, Nashville.

Address correspondence to Brooke Lemmen, DO, at brooke.lemmen@uofmhealth.org.

Author Disclosure: No relevant financial relationships.

  1. 1.Wang D, Wright JM, Adams SP, et al. Pharmacotherapy for mild hyper tension. Cochrane Database Syst Rev. 2025(9):CD006742.
  2. 2.Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev. 2025(10):CD000028.
  3. 3.Gnjidic D, Langford AV, Jordan V, et al. Withdrawal of anti hypertensive drugs in older people. Cochrane Database Syst Rev. 2025(3):CD012572.
  4. 4.Jones DW, Ferdinand KC, Taler SJ, et al.; Peer Review Committee members. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567-1678.
  5. 5.Coles S, Fisher L, Lin KW, et al. Blood pressure targets in adults with hypertension: a clinical practice guideline from the AAFP. Am Fam Physician. 2022;106(6) ): online. Accessed August 17, 2026. https://www.aafp.org/afp/2022/1200/practice-guidelines-aafphypertension-full-guideline

Copyright ©2026 MD Aware, LLC (theNNT.com). Used with permission.

This series is coordinated by Christopher W. Bunt, MD, AFP assistant medical editor, and the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https:// www.aafp.org/afp/mbtn.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.